Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Trial Of Sublingual-Oral Immunotherapy (SLIT) In Adults With Allergic Rhinoconjunctivitis Caused By Ragweed Pollen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2015
Price :
$35
*
At a glance
- Drugs Ragweed allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Asthma; Ragweed pollen hypersensitivity
- Focus Registrational; Therapeutic Use
- 11 Dec 2013 Results published in the Journal of Allergy and Clinical Immunology.
- 26 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 12 Jun 2012 Primary endpoint 'Symptom-score' has been met, according to a Greer Laboratories media release.